Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1

Gut

Volumn 61, Issue 10, 2012, Pages 1473-1480

  Serfaty, Lawrence ^a   Forns, Xavier ^b   Goeser, Tobias ^c   Ferenci, Peter ^d   Nevens, Frederik ^e   Carosi, Giampiero ^f   Drenth, Joost P ^g   Lonjon Domanec, Isabelle ^h   DeMasi, Ralph ⁱ   Picchio, Gaston ⁱ   Beumont, Maria ^j   Marcellin, Patrick ^k  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF BRESCIA   (Italy)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Janssen Pharmaceuticals   (France)

ⁱ Tibotec Inc   (United States)

^j TIBOTEC BVBA   (Belgium)

^k BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84866060640     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300749     Document Type: Article

References (29)

1. Bressler BL, Guindi M, Tomlinson G, et al . High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
2. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
3. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
4. Chu CJ, Lee SD, Hung TH, et al . Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009;29:46-54.
5. Jian Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006;26:166-72.
6. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7.
7. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin are major predictors of liver fibrosis and response to pegylated and ribavirin in genotype 4 chronic hepatitis C patients. J Hepatol 2009;50:S233-4.
8. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34.
9. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-23.
10. Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75:355-9.
11. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
12. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009;29(Suppl 2):13-25.
13. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44.
14. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68. e1.
15. McHutchison JG, Everson GT, Gordon SC, et al . Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38. Erratum in: N Engl J Med 2009;361:1516.
16. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-29.
18. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
19. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
20. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
21. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34:297-305.
22. Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011;55:1187-94.
23. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
24. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010;52:854-63.
25. Li JH, Lao XQ, Tillmann HL, et al. Interferon-lambda genotype and low serum lowdensity lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904-11.
26. Pazienza V, Clément S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype specific mechanisms. Hepatology 2007;45:1164-71.
27. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010;59:1694-8.
28. Fattovich G, Covolo L, Pasino M, et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011;31:66-74.
29. Prati GM, Rumi MG, Aghemo A, et al. Insulin resistance does not predict a response to pegylated interferon plus ribavirin in chronic hepatits C patients: a sub-analysis of the MIST study. J Hepatol 2010;52:S122.